- 2022년 8월 9일
Bukwang announces patent registration of SOL-804 in 32 countries
registration in more 6 countries, including Korea in this year Bukwang Pharmaceutical Co., Ltd. (Bukwang) announced that the composition...
- 2022년 3월 30일
Bukwang Announces the result of SOL-804’s Phase 1 clinical trial
Result : It has similar pharmacokinetic properties with low-doses compared to the control group with high-doses. Bukwang will decide the...
- 2022년 2월 24일
Bukwang Announces Completion of SOL-804’s Phase 1 clinical trial
- The result will be shown in March : to confirm the equivalent effectiveness with low doses compared to the control medicine - This...
- 2022년 2월 21일
Bukwang accelerates globalization together with OCI
Aiming to become a global pharma through synergy between the two companies On 22nd February, Bukwang’s affiliated person entered into a...
- 2022년 1월 4일
Bukwang expanded the partnership of ‘Aprovel and CoAprovel’ to General Hospitals
-Bukwang made a contract with Sanofi-Aventis Korea on sales-marketing expansion Bukwang Pharmaceutical(CEO Yoo Hee Won) announced that...
- 2021년 12월 21일
Bukwang initiates dosing of SOL-804 in the phase 1 study
- an improved treatment of prostate cancer ,the study will be ended within the first half of 2022 Bukwang Pharmaceutical Co., Ltd....
- 2021년 12월 15일
Bukwang received approval of a new drug ‘Ozanex cream’ , a topical antibiotic
-A short-term topical impetigo treatment from Ferrer Healthcare, Spain -It is a new drug approved from FDA and EMA and also will be...
- 2021년 11월 11일
Bukwang registered a composition patent for SOL-804 in the U.S.
approved in the U.S.,Europe, Japan, Eurasia, Australia, and Mexico Bukwang Pharmaceutical (“Bukwang”) announced that its subsidiary, Dyna...
- 2021년 10월 21일
Approval of phase 1 clinical study for anticancer drug, SOL-804
The modified drug for metastatic castration-resistant prostate cancer, expectation of the fast result Bukwang Pharmaceutical announced...
- 2021년 7월 8일
Contera Pharma, a subsidiary of Bukwang, has partnership with Abzu
to design RNA therapeutics for rare diseases using x AI technology Contera Pharma, a subsidiary of Bukwang, is focused on developing new...
